BARDA Funding Tracker

Tracker Details Billions in Taxpayer Funds Supporting COVID-19 R&D Efforts

The U.S. government is spending billions of dollars advancing COVID-19 tests, treatments, and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Department of Health and Human Services, is one of the federal entities leading this effort. In the tables below, we describe BARDA funding awards to date. These include awards for research, development, manufacturing, and procurement.

Last updated September 24, 2020

 

$13,319,213,992 BARDA COVID-19 Funding

BARDA has spent billions advancing COVID-19 tests, treatments, and vaccines.

COVID-19 BARDA Funding Summary

Type of ProductCountTotal AwardedAverage AwardLowest AwardHighest AwardProportion of Total Award
Diagnostic3684,701,419


2,732,304

111,090
13,692,3700.6%
Therapeutic9945,556,899
105,061,878
7,200,000617,724,874
7.1%
Vaccine811,064,025,492
1,383,003,187
38,033,570
2,479,894,979

83.1%
Other537,926,0447,585,209592,79134,893,0330.3%
Vaccine Administration8391,486,985
55,926,712
432,990
204,000,0002.9%
Rapidly Deployable Capabilities47,517,153
1,879,288
720,0003,833,3630.1%
Vaccine/Therapeutic Manufacturing2788,000,000
394,000,000
160,000,000
628,000,0005.9%
Total7213,319,213,992
201,806,273

111,090
2,479,894,979

 

COVID-19 BARDA Funding Database

Methods: We aggregated entries from the BARDA COVID-19 website. Where indicated, we supplemented the database using press releases.

CorporationProductDescription (quoted excerpt from BARDA)Amount AwardedType of ProductDate (Last modified)Notes
CepheidXpert Xpress SARS-CoV-2 testDevelopment of a Xpert Xpress SARS-CoV-2 rapid diagnostic assay3700000Diagnostic2/25/2020
ChembioDPP® COVID-19 Ag SystemSARS-CoV-2 point-of-care antigen detection assay, using Chembio’s patented DPP® (lateral flow based) and DPP Micro Reader for diagnosis of COVID-19 from respiratory specimens.628071Diagnostic7/6/2020
Cue Inc.Point-of-Care COVID-19The Cue Health Monitoring System w/SARS CoV-2 cartridge is a small, portable sample-to-answer system designed for point-of-care and home use.13692370Diagnostic3/21/2020
DiaSorin Inc.LIAISON SARS-CoV-2 IgMTest
A serology test to detect IgM antibodies against SARS-CoV-2 in human serum or plasma, using chemiluminescent immunoassay technology on the fully automated LIAISON® XL platform. The development of this test is being funded by a modification to our existing award with DiaSorin Inc.111090
Diagnostic8/6/2020
DiaSorin Inc.Liaison SARS-CoV-2 S1/S2 IgGSerology (antibody) test for COVID-19 on the LIAISON XL platform. This new COVID-19 test is a fully automated, chemiluminescent immunoassay for the qualitative detection of IgG class antibodies against the SARS-CoV-2 virus.180045Diagnostic4/10/2020
DiaSorin Molecular LLCSimplexaTM COVID-19 Direct AssayDevelopment of SimplexaTM COVID-19 Direct Assay

697423Diagnostic3/11/2020
Empatica, Inc.AuraAura is an early warning platform for COVID-19 infection. This diagnostics platform enables continuous and real-time insight into infection likelihood before symptoms present, through the use of a wearable device and an algorithm that can continuously monitor physiological health markers and produce an output.717807Diagnostic6/18/2020
GenMark Diagnostics, Inc.ePlex Respiratory Pathogen v2 PanelAn expanded version of GenMarks’s FDA cleared ePlex Respiratory Pathogen (RP) Panel to include assays for the simultaneous detection of SARS-CoV-2 and other respiratory pathogens.749000Diagnostic3/20/2020
HememicsRapid SARS-CoV-2 Antibody Test for HemBox™ Biosensor SystemHemBox™ is a Bluetooth-connected POC diagnostic device currently in development for 60-second identification of up to 17 pathogens. This test will detect the presence of SARS-CoV-2 antibodies in 1 drop of blood. This is the same award as the Hememics antigen test. A single award of $638,000 is funding development of the antigen and antibody tests.638000Diagnostic4/9/2020
HememicsRapid SARS-CoV-2 Antigen Test for HemBox™ Biosensor SystemHemBox™ is a Bluetooth-connected POC diagnostic device currently in development for 60-second identification of up to 17 pathogens. This test will detect the presence of SARS-CoV-2 antigen in nasal swabs. This is the same award as the Hememics antibody test. A single award of $638,000 is funding development of the antigen and antibody tests.N/ADiagnostic4/9/2020
Hologic, Inc.COVID-19 Testing ProductsExpanding production of custom sample collection and processing consumables for COVID-19 tests
7600000
Diagnostic7/26/2020Link
Hologic, Inc.Aptima® SARS-CoV-2 assayThe Aptima® SARS-CoV-2 assay is a molecular diagnostic test that detects SARS-CoV-2, the virus that causes COVID-19 disease, in respiratory specimens. This assay is being developed for use on the Hologic Panther System which is a fully automated, high-throughput molecular diagnostic platform with over 1,000 instruments installed in the U.S.13000000Diagnostic4/29/2020
Hologic, Inc.Panther Fusion SARS-CoV-2 AssayA SARS-CoV-2 Diagnostic Assay based on the widely-used Panther Fusion platform699000Diagnostic3/6/2020
Immunexpress Inc.SeptiCyte RAPID Host-Based Sepsis In Vitro DiagnosticSeptiCyte® RAPID is a host response gene expression, blood-based diagnostic for rapid identification of sepsis that will be evaluated to triage COVID-19 patients for severe outcomes (sepsis) in the ICU and ED.599549Diagnostic6/11/2020
InBios International, Inc.SCoV-2 Ab Detect™ Rapid TestSARS-CoV-2 Ab Detect™ Rapid Test, is a lateral flow serodiagnostic test that will use blood products, including fingerprick blood, to identify persons infected with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. This point-of-care assay will detect SCoV-2 reactive antibodies as host biomarkers.594943Diagnostic4/27/2020
LuminexARIES SARS-CoV-2 AssayLuminex Corporation will develop a sample-to-answer SARS-CoV-2 assay on its IVD ARIES® molecular diagnostic system that can be run in moderate complexity labs.642450Diagnostic3/27/2020
LuminexNxTAG CoV Extended PanelThe testing protocol for the NxTAG CoV Extended Panel involves extraction on a bioMerieux system, amplification using Eppendorf mastercycler, and amplicon detection using the Luminex MAGPIX system.642450Diagnostic3/26/2020
Luminex
xMAP SARS-CoV-2 Advanced Serology AssaySARS-CoV-2 Advanced Serology Assay for use with the MAGPIX®, Luminex® 200™ IVD xMAP®, and FLEXMAP 3D® Platforms.683500
Diagnostic9/23/2020
LuminexNxTAG® Respiratory Pathogen Panel v2
In this project, viral targets on the NxTAG® Respiratory Pathogen Panel (RPP) will be updated, the SARS-CoV-2 target will be added, and the combined panel will be submitted for 510(k) to provide customers a more accurate, longer term syndromic testing solution.5389813
Diagnostic
9/24/2020
MBio Diagnostics, Inc.MBio COVID-19 Antibody PanelThe MBio COVID-19 Antibody Panel is a high performance point-of-care for seroprevalence studies, to assess exposure and potential immunity to SARS-CoV-2 virus. It may be used an orthogonal method to confirm positive results reported by another method.629595Diagnostic6/17/2020
Mesa Tech InternationalAcula COVID-19 Diagnostics TestDevelopment of the Accula COVID-19 point-of-care test to request Emergency Use Authorization (EUA) from the FDA within two months of the award.561330Diagnostic3/13/2020
NanomixRapid Antibody Test for COVID-19Development of a COVID-19 rapid mobile test to diagnose infection in as little as 15 minutes. The test detects the presence of SARS-CoV-2 antibodies in blood, to indicate current or past COVID-19 infection. This is the same award as the Nanomix antigen test. A single award of $569,647 is funding development of the antigen and antibody tests.569647Diagnostic4/2/2020
NanomixRapid Antigen Test for COVID-19Development of a COVID-19 rapid mobile test to diagnose infection is as little as 15 minutes. The test detects the presence of SARS-CoV-2 antigen in nasal and throat swabs. This is the same award as the Nanomix antibody test. A single award of $569,647 is funding development of the antigen and antibody tests.N/ADiagnostic4/2/2020
NOWDiagnostics Inc.
ADEXUSDx® COVID-19 Test
The ADEXUSDx® COVID-19 test is a rapid and accurate point of care lateral flow assay for detection of SARS-CoV-2 antibodies in blood that utilizes the NOWDiagnostics® ADEXUSDx® device platform. This platform is already commercialized for other tests, including an FDA cleared professional use pregnancy test that is CE marked for self-testing.
695500
Diagnostic
8/27/2020
OraSure Technologies, IncOraQuick® Coronavirus Rapid Antigen TestRapid Coronavirus point-of-care test (POC) and potentially in-home, minimally invasive, appropriate for oral fluid and capable of providing results in 30 minutes.710310Diagnostic4/2/2020
OraSure Technologies, IncELISA based Coronavirus Antibody TestELISA based Coronavirus Antibody Test and non-invasive collection device for the detection of anti-SARS-CoV-2 antibodies in oral fluid specimens. Sample collection can be obtained at home, promoting social distancing and reducing risk to health workers.629217Diagnostic6/5/2020
Ortho Clinical DiagnosticsVITROS® Anti-SARS-CoV-2 IgG TestHigh-accuracy immunoassay for the qualitative detection of IgG antibodies to SARS-CoV-2 – which appear in later phases of infection and remain elevated after recovery – offered on random-access, high throughout laboratory instruments. One award of $678,000 is funding continued development of this assay and the Ortho total antibody test.13528000
Diagnostic6/12/2020
Additional funding for the IgG test and Total tests and new funding for the Ag (Antigen) Test was awarded on 9/18/20, totaling $12.85 million. This built on earlier funding of $678,000.
Ortho Clinical DiagnosticsVITROS® Anti-SARS-CoV-2 Total TestHigh-accuracy immunoassay for the qualitative detection of total (IgG, IgM, IgA, and other) antibodies to SARS-CoV-2 – offered on random-access, high throughout laboratory instruments. One award of $678,000 is funding continued development of this assay and the Ortho IgG test.N/ADiagnostic6/12/2020
Ortho Clinical DiagnosticsVITROS® SARS-CoV-2 Ag (Antigen) TestHigh accuracy immunoassay, for the semi-quantitative detection of Total and IgG antibodies to SARS-CoV-2 & for the qualitative detection of SARS-CoV-2 antigens.N/A
Diagnostic
9/18/2020
Qiagen, LLCQIAstat-Dx Respiratory SARS-CoV-2 PanelQiagen will develop a COVID-19 test, QIAstat-Dx RPS2, to be added to the QIAstat-Dx Respiratory Panel.598191Diagnostic3/12/2020
Quidel Corporation Point of Care SARS-CoV-2 Sofia 2 Antigen AssayImplement SARS-CoV-2 viral antigen assay into a 4-analyte antigen test (SARS-CoV-2, RSV, Flu A and Flu B) on the Quidel Sofia 2 POC Multiplex platform.634643Diagnostic5/29/2020
Siemens HealthineersAtellica® IMT SARS-CoV-2 Total (COV2T) assayThe SARS-CoV-2 Total (COV2T) assay is a chemiluminescent immunoassay intended for qualitative detection of total antibodies (including IgG and IgM) to SARS-CoV-2 in human serum and plasma (EDTA and lithium heparin) using the Atellica® IMT system. One award of $602,275 is funding continued development of this assay and the ADVIA Centaur® assay.13602275
Diagnostic5/29/2020
$13,000,000 in additional funding for both the Atellica and ADVIA assays was awarded on 9/17/20. This built on earlier funding of $602275.
Siemens HealthineersADVIA Centaur® SARS-CoV-2 Total (COV2T) assayThe ADVIA Centaur® SARS-CoV-2 Total (COV2T) assay is a chemiluminescent immunoassay intended for qualitative detection of total antibodies (including IgG and IgM) to SARS-CoV-2 in human serum and plasma (EDTA and lithium heparin) using the ADVIA Centaur® XP and ADVIA Centaur® XPT systems.N/ADiagnostic5/29/2020

Sonica HealthSonica's Bio-Integrated, Wireless Sensor System (ADAM) SystemIndividuals infected with SARS-CoV-2 and similar viruses typically only seek diagnostic tests once they begin exhibiting symptoms. Sonica aims to disrupt this health-care paradigm by detecting infection in individuals before the onset of noticeable symptoms.656420Diagnostic6/29/2020
Tangen BiosciencesTangen SARS-SoV-2 AssayDevelopment of a Point of Care SARS-CoV-2 Assay for use with the Tangen GeneSpark Molecular diagnostic system696000Diagnostic4/15/2020
Vela Diagnostics USA, Inc.ViroKeyTM SARS-CoV-2 RT-PCRProbe-based reverse transcriptase PCR (RT-PCR) test224780Diagnostic3/27/2020
Cerus CorporationIntercept Blood SystemThe Cerus INTERCEPT Blood System reduces the risk of transfusion-transmitted infections from bacteria and other blood-borne pathogens1048348Other4/18/2020
Colorado State UniversitySolaVAX Vaccine DevelopmentSolaVAX™ is an inactivated virus vaccine platform that uses Riboflavin and UV light to selectively inactivate virus particles by directed damage to nucleic acids while preserving the integrity of the proteins and viral antigens.699994Other6/25/2020Link
Phillips North AmericaPhillips Lumify UltrasoundsBARDA & Philips Research are collaborating to expand the capability of their compact Philips Lumify, an AI-based multi-functional hand-held ultrasound system, with predictive machine-learning (ML) algorithms, to provide Automatic and Intelligent Quantitative Assessment of Lung Injuries, Diseases and Traumatic Injuries in a Mass-Casualty Incident.34893033.36Other5/8/2020
Snapdragon Chemisty, Inc.Continuous Manufacturing for Ribonucleotide TriphosphatesRapidly scalable continuous manufacturing platform for the chemical synthesis and purification of ribonucleotide triphosphates (NPT) from shelf-stable ribonucleotide.691878Other6/11/2020
Link
VitalConnectVista SolutionVista Solution is an FDA cleared remote patient monitoring system for use within hospital, nursing home facilities, and homes. Vista Solution is comprised of the VitalPatch biosensor, a tablet where vital signs are viewed and transmitted to a central cloud, a secure cloud, and a central monitoring hub.592791Other5/20/2020
Becton DickinsonNeedles and syringesNeedles and syringes42000000Vaccine Administration7/8/2020
Link
Joint with JPEO-CBRND
Corning IncorporatedCorning Valor® Glass vialsVaccine vials204000000Vaccine Administration6/9/2020
Link
Joint with JPEO-CBRND
Esperovax, Inc
Egress RD mRNA Oral Cellular Vaccine Delivery Technology
An oral immunization for COVID-19 involving delivery of enveloped virus like particles (eVLPs) by capsule to the gut that will induce immune protection against disease.
606780
Vaccine Administration
7/28/2020
University of Connecticut
Single-Administration Microneedle Skin Patch for Pandemic Vaccine
An easy-to-use vaccine-delivery microneedle (MN) patch (i.e., Micro Array Patch) that will contain the spike protein (the S-protein on the shell of COVID-19 virus) and be programmed to automatically deliver this S-protein (as an antigen against COVID-19) into the skin.
432990
Vaccine Administration
8/17/2020
Vaxess Technologies, Inc.MIMIX-COVID Pre-fusion Spike Protein Micro Array PatchMIMIX Vaccine Patch Development and Scaling of shelf-stable, self-applied, single-dose Micro Array Patch (MAP) technology
749000
Vaccine Administration
8/9/2020
Verndari, Inc.
VaxiPatch™ Complete Vaccination Kit
SARS-CoV-2 Recombinant Spike Receptor Binding Domain protein administered via Micro Array Patch (MAP) Technology
698215
Vaccine Administration
7/23/2020
SiO2 Materials ScienceVaccine vialsVaccine vials143000000Vaccine Administration6/8/2020
Link
Joint with JPEO-CBRND
Retractable Technologies, Inc.Needles and syringesNeedles and syringes53664286 Vaccine Administration7/1/2020
Link
Joint with JPEO-CBRND
98point6
Text-based virtual care to assess, diagnose and treat COVID-19The 98point6 primary care platform combines a telehealth service with AI and machine learning to provide a comprehensive program of diagnosis, assessment, triage, reporting and tracking of SARS-CoV-2 infections to a national population of patients.700000
Rapidly Deployable Capabilities9/10/2020
Beckman CoulterMonocyte Distribution Width (MDW) and Algorithms for Sepsis DetectionBeckman Coulter, in collaboration with Dascena, Inc., is developing a novel machine-learning-based sepsis detection algorithm for regulatory clearance that combines laboratory test parameter values with electronic health record information to accurately predict and detect sepsis earlier.2263790Rapidly Deployable Capabilities5/15/2020
Cytovale Inc.Rapid Sepsis DiagnosticCytovale’s rapid sepsis diagnostic leverages advances in microfluidics, ultra-high speed imaging, and machine learning to rapidly quantify immune cell dysregulation from a blood sample in minutes to predict the likelihood of sepsis.3833363Rapidly Deployable Capabilities4/7/2020
Evidation HelathCOVID-19 Detection & Forecasting Model PilotEvidation seeks to develop a model that can detect whether an individual has likely been infected with COVID-19 and understand an individual’s susceptibility to infection.720000Rapidly Deployable Capabilities4/17/2020
AstraZenecaAstraZeneca SARS-CoV-2 monoclonal antibody combinationA novel monoclonal antibody combination that recognizes and neutralizes SARS-CoV-2 is being developed by AstraZeneca with DARPA and BARDA as a potential preventative and post-exposure treatment to combat COVID-19.23650000Therapeutic6/2/2020
Emergent BiosolutionsHuman immune Globulin for COVID-19 (COVID-19 HIG)HIG is derived from plasma donated by individuals who have recovered from COVID-19. This plasma contains antibodies that target the SARS-CoV-2 virus. Using their established manufacturing process that supports VIGIV, Anthrasil and other FDA approved products, Emergent will purify and concentrate the virus-targeting antibodies into a drug product that can be administered intravenously as a potential therapeutic.14531801Therapeutic4/2/2020
Genentech USA, Inc.MSTT1041A (anti-ST2) and UTTR1147A (IL-22Fc)ST2 is the receptor for IL-33. Inhibition of IL-33 signaling via inhibition of ST2 is predicted to reduce maladaptive hyperinflammatory responses. IL22 is a cytokine that promotes epithelial and endothelial cell repair and may prevent secondary bacterial infections.22600000Therapeutic5/28/2020
Genetech USA, Inc.ACTEMRA (tocilizumab)Tocilizumab is a recombinant anti-human monoclonal antibody directed against the interleukin-6 receptor (IL-6R)25100000Therapeutic3/27/2020
Grifols Shared Services North America, Inc. (Grifols)Convalescent plasma and hyperimmune globulinBoth products originate from plasma donated by individuals who have recovered from COVID-19. This plasma contains antibodies that specifically target the SARS-CoV-2 virus. To produce convalescent plasma, the donated plasma will be pathogen inactivated and made available in units for infusion as an investigational therapeutic. Grifols will also purify and concentrate the virus-targeting antibodies into an investigational therapeutic called hyperimmune globulin.12551764.05Therapeutic4/7/2020
Janssen Research & Development, LLCSARS-CoV-2 Therapeutic Drug Screening EffortsJanssen, in collaboration with Rega Institute of Medical Research, will screen libraries to identify therapeutic compounds with antiviral activity against 2019-nCoV.152312126Therapeutic2/14/2020
Regeneron Pharmaceuticals, IncREGN-COV2 (SARS-CoV-2 specific monoclonal antibodies)Develop multiple monoclonal antibodies that, individually or in combination, could be used against the novel coronavirus SARS-CoV-2 that causes COVID-19617724874Therapeutic7/6/2020
Regeneron Pharmaceuticals, IncSarilumabKevzara (sarilumab) is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor.69886334TherapeuticNo longer supported
SAb Biotherapeutics, Inc.SAB-185SAB-185 is a novel high-potency immunotherapy candidate designed to treat COVID-19. The therapy delivers human polyclonal antibodies targeted specifically to the SARS-CoV-2 virus, that are generated, collected and purified using SAB’s proprietary in vivo platform technology, without the need for human donors or serum from recovered coronavirus patients.7200000Therapeutic3/30/2020
AstraZenecaAZD1222 (formerly ChAdOx1 nCoV-19 vaccine)The AZD1222 vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the structural surface glycoprotein (Spike protein) antigen of the SARS CoV-2 (nCoV-19)1200000000Vaccine5/20/2020
Janssen Research & Development, LLCViral Vector Vaccine for COVID-19Support development to licensure of a vaccine to combat COVID-19 using Janssen’s established Adenovirus 26 platform, plus demonstration of Janssen's capacity to perform large scale manufacturing domestically of up to 100 million doses of its SARS-CoV-2 vaccine, Ad26.COV2.S1457887080
Vaccine8/5/2020
Merck and IAVIrVSVΔG-CoV2Recombinant vesicular stomatitis virus (VSVΔG)-vectored vaccine expressing the spike protein of SARS-CoV-2.38033570Vaccine4/15/2020
ModernaTX, Inc.SARS-CoV-2 mRNA-1273 vaccinemRNA based SARS-CoV-2 vaccine encoding a pre-fusion stabilized Spike protein2479894979Vaccine5/24/2020
Novavax, Inc.NVX-CoV-2373 Vaccine for SARS-CoV-2Manufacture and delivery of SARS-CoV-2 vaccine doses, NVX-CoV2373, which is suitable for use in humans under a sufficiently informed deployment strategy, and the advanced positioning of a stockpile of critical long lead raw materials for the Matrix-M adjuvant. The NVX-CoV-2373 vaccine is comprised of the Matrix-M™ adjuvant, and antigen (SARS-CoV-2 spike protein).1600434523Vaccine7/6/2020
Pfizer Inc.
BNT162, a prototype COVID-19 mRNA vaccine
Pfizer will conduct large-scale manufacturing and fill-finish of 100M doses of its prototype COVID-19 mRNA vaccine, developed in collaboration with BioNTech, for distribution in the US once Emergency Use Authorization or licensure is granted by the FDA.1950000000
Vaccine7/22/2020
Sanofi and GlaxoSmithKline
Recombinant SARS-CoV-2 Protein Antigen + AS03 Adjuvant
Recombinant SARS-CoV-2 spike protein with transmembrane region deleted produced using Sanofi’s FDA-licensed seasonal influenza vaccine Flublok® facilities, adjuvanted with GSK's AS032072775340
Vaccine7/31/2020
Texas Center for Innovation in Advanced Development and Manufacturing
Additional manufacturing capacity for COVID-19 VaccinesAdditional manufacturing capacity for COVID-19 Vaccines265000000
Vaccine7/27/2020Link
Emergent BioSolutionsN/AAdditional manufacturing capacity for Operation Warp Speed candidates628000000Vaccine/Therapeutic Manufacturing6/1/2020
Link
Grand River Aseptic ManufacturingN/AManufacturing capacity for vaccine and therapeutic candidates160000000
Vaccine/Therapeutic Manufacturing8/3/2020
Link
TOTAL13,319,213,992